
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is expected to thrive under its new structure, as demonstrated by its strong organic growth and increased guidance across all financial metrics. With the separation of the purification and filtration segment and a potential sale or spinoff of the HIS segment, Solventum is on track to maximize shareholder value and unlock the conglomerate discount currently weighing down its stock. Additionally, factors such as improved execution, faster debt paydown, and positive updates on the HIS separation could drive further upside to our already bullish outlook.
Bears say
Solventum is a company that has undergone significant transformation and divestitures in its various business segments, including selling off its smaller purification and filtration segment and announcing plans to separate its healthcare information systems business. In addition, while the company's organic growth in its medsurg segment has been strong, there are concerns about its overreliance on one product (Tegaderm CHG) within the segment and potential timing delays in its ERP implementation. Furthermore, the recent changes to gross margins and operating expenses are expected to impact the company's overall profitability in the near term, with hopes of improvement in the following year.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares